Monitor APOLLO topline data in Q4 2026 and RESTORE-PV initial data in Q3 2026 as key catalysts. The FDA alignment reduces regulatory risk for bitopertin, and the accelerated enrollment timeline for DISC-3405 suggests strong investigator interest. Cash runway into 2029 provides ample funding through these milestones.
IRON drugs
IRON drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $79.21entry
- T+1 · 4mo ago −2.79%α −3.50% · $77.00
- T+5 · 3mo ago −2.23%α −5.86% · $77.44
- T+20 · 3mo ago +4.22%α +0.25% · $82.55
- T+60 · 25d ago −5.93%α −8.40% · $74.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is the completed Type A FDA meeting aligning that the Phase 3 APOLLO trial of bitopertin in EPP, if successful, can serve as the basis for a CRL response, with topline data expected in Q4 2026. The company also completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405, with initial data now expected in Q3 2026, ahead of schedule.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $59.5M ($1.54/share) vs $55.2M ($1.58/share) in Q2 2025, beating consensus of -$1.77
- Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026, providing runway into 2029
- Completed Type A meeting with FDA; Phase 3 APOLLO topline data for bitopertin in EPP expected Q4 2026
- Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera; initial data expected Q3 2026
- Selcodebart (DISC-0974) received EU Orphan Drug Designation for myelofibrosis; updated RALLY-MF data presented at ASCO/EHA
Financial Impact
Net loss of $59.5M in Q2 2026, slightly wider than $55.2M in Q2 2025; cash burn rate consistent with prior quarter
Risk Factors
- Phase 3 APOLLO trial failure would significantly impair bitopertin's regulatory path
- Clinical-stage biotech with no approved products or revenue; relies on successful pipeline advancement
- Cash burn rate may increase as multiple programs advance into later-stage trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336047 |
Track record
43 reports on IRON
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers